VCU Health Leads Clinical Trial For New treatment To Help People With Bowel Control Problems

A research team at VCU Health is leading a clinical trial to assess a novel treatment for fecal incontinence or sudden loss of control over bowel movements. The therapy involves implanting a bioengineered sphincter derived from the patient’s native cells to help them regain control of their bowels.  The implantation surgery for the clinical trial is being led by Jaime Bohl, M.D., an associate professor in the Department of Surgery and chief of the Division of Colon and Rectal Surgery at Virginia Commonwealth University’s School of Medicine. Read more.

Source: VCU Health, February 28, 2024

Could Botox Injections Help Patients…Down There? A New Study Suggests That Botox Can Help with Fecal Incontinence

Researchers are testing rectal injections of Botox to see whether they might help patients manage fecal incontinence—so far, results are promising. If future studies confirm success, doctors could provide patients with new ways to manage this hard-to-control condition.  In a randomized, double-blind, placebo-controlled study, researchers treated nearly 200 patients for fecal incontinence using Botox or a placebo. Ninety-six patients received Botox, and 95 received the placebo treatment after nine patients withdrew from the trial before receiving injections.  Read more.

Source: MDLinx, January 29, 2024

female doctor

Medical Device Maker Boston Scientific to Buy Axonics for $3.7 Billion

Medical device maker Boston Scientific (BSX.N), said on Monday it had agreed to buy Axonics Inc (AXNX.O), for $3.7 billion, gaining access to devices used to improve bladder function.  The deal marks Boston Scientific’s entry into sacral neuromodulation, a minimally invasive procedure used in the treatment of overactive bladder and fecal incontinence, and is the latest in efforts to scale up its urology business. Read more.
Source: Reuters, January 8, 2024
business buildings

Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration has approved the company’s fourth-generation rechargeable sacral neuromodulation system. The newly approved Axonics R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to just once every 6 to 10 months for only one hour.  Read more.

Source: BusinessWire, January 31, 2023